WPP plc Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights – WPP

(NYSE:WPP), LOS ANGELES, Nov. 03, 2025 (GLOBE NEWSWIRE) — The DJS Law Group reminds investors of a class action lawsuit against WPP plc (“WPP” or “the Company”) (NYSE: WPP) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders […]

Marex Group plc Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights – MRX

(NASDAQ:MRX), LOS ANGELES, Nov. 03, 2025 (GLOBE NEWSWIRE) — The DJS Law Group reminds investors of a class action lawsuit against Marex Group plc (“Marex” or “the Company”) (NASDAQ: MRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Molina Healthcare, Inc. Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights – MOH

(NYSE:MOH), LOS ANGELES, Nov. 03, 2025 (GLOBE NEWSWIRE) — The DJS Law Group reminds investors of a class action lawsuit against Molina Healthcare, Inc. (“Molina” or “the Company”) (NYSE: MOH) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Data Presented at the 2025 Southern Region Burn Conference Reinforce RECELL(R) System as a Standard of Care in Acute Wound Treatment

(AUST:AVH.AX),(NASDAQ:RCEL), VALENCIA, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) — AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical,” or the “Company”), a leading therapeutic acute wound care company, today announced two podium presentations at the 2025 Southern Region Burn Conference (SRBC) that collectively underscore the clinical and economic value of the RECELL System and reinforce

Brag House Holdings, Inc., to Create New Financial Powerhouse Anchored by Payments, Asset Management, and RWA Strategy with House of Doge – The Official Corporate Arm of the Dogecoin Foundation

(NASDAQ:TBH), NEW YORK and MIAMI, Nov. 03, 2025 (GLOBE NEWSWIRE) — Brag House Holdings, Inc. (NASDAQ: TBH) (“Brag House”) and its merger partner, House of Doge Inc. (“House of Doge”), the official corporate arm of the Dogecoin Foundation, today provided a strategic update on their definitive merger agreement. The merger is set to create a

LiveOne (Nasdaq: LVO) Accelerates Revenue Growth with Intuizi AI, Driving Tesla Subscriber Conversions

(NASDAQ:LVO), Key Insights: Tesla ad-supported subscribers have grown to 1M+ over the last year 60% ARPU increase to over $5 31%+ increase in subscription engagement since launch 22%+ increase in Plus/Premium conversions since launch LOS ANGELES, Nov. 03, 2025 (GLOBE NEWSWIRE) — LiveOne, Inc. (Nasdaq: LVO), a leading music, entertainment, and social platform delivering premium

Worksport ($WKSP) to Showcase SOLIS(TM) and COR(TM) at SEMA 2025, Expanding Global Distribution Opportunities

(NASDAQ:WKSP), Company to Meet Dealers, Distributors and Showcase Industry-Defining Clean-Tech Solutions — SOLIS Solar Tonneau and COR Portable Energy System — in SEMA's “New Product” Evaluation Category West Seneca, New York, Nov. 03, 2025 (GLOBE NEWSWIRE) — Worksport Ltd. (NASDAQ: WKSP) (“Worksport” or the “Company”), a U.S.-based innovator in advanced manufacturing and distributed clean energy

Achieve Life Sciences Meets Key Milestones Advancing Cytisinicline NDA for Smoking Cessation

(NASDAQ:ACHV), 120-Day Safety Update Submitted to FDA ORCA-OL Long-Term Safety Trial Successfully ConcludedDSMC Completes Final Review of Cytisinicline, Finds No Drug Safety Concerns SEATTLE and VANCOUVER, British Columbia, Nov. 03, 2025 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as

Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025

(NASDAQ:IMMX), – Oral presentation Sunday, December 7, at ASH 2025 – LOS ANGELES, Nov. 03, 2025 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced that Phase 1/2 interim results from its U.S. NXC-201 NEXICART-2 trial in relapsed/refractory AL Amyloidosis has been

IRADIMED CORPORATION Reports Record Third Quarter 2025 Financial Results

(NasdaqGM:IRMD), Reports record revenue of $21.2 million for the third quarter of 2025, an increase of $2.9 million, or 16%, compared to the same period in 2024. Reports record GAAP diluted EPS of $0.43 and non-GAAP diluted EPS of $0.47 for the third quarter of 2025, which are increases of 8% and 9%, respectively, compared

Scroll to Top